Evidence map›Paper›PMID 28350842›Full record

ArticlePloS one2017

Combination of mesenchymal stem cell injection with icariin for the treatment of diabetes-associated erectile dysfunction.

Xiyou Wang, Chuanhai Liu, Yong Xu, Ping Chen, Yue Shen, Yansheng Xu, Yubo Zhao, Weihao Chen, Xinyu Zhang, Yun Ouyang and 4 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed, 1 pooled it
9.1field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 1 synthesis or guideline pooled it, 61 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Review
  10. Review
  11. Article
  12. Review
  13. Article
  14. Icariin enhances AMP-activated protein kinase and prevents high fructose and high salt-induced metabolic syndrome in rats.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2020
    Article
  15. Review
  16. Article
  17. Review
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

14 authors at 3 institutions in 1 country.

Xiyou WangDepartment of Urology, PLA Navy General Hospital, Hai dian District, Beijing, People's Republic of China.
Chuanhai LiuDepartment of Urology, The Second Artillery General Hospital of Chinese People's Liberation Army, Xicheng District, Beijing, People's Republic of China.
Yong XuDepartment of Urology, PLA General Hospital, Hai dian District, Beijing, People's Republic of China.
Ping ChenDepartment of Urology, PLA Navy General Hospital, Hai dian District, Beijing, People's Republic of China.
Yue ShenDepartment of Urology, PLA Navy General Hospital, Hai dian District, Beijing, People's Republic of China.
Yansheng XuDepartment of Urology, PLA Navy General Hospital, Hai dian District, Beijing, People's Republic of China.
Yubo ZhaoDepartment of Urology, PLA Navy General Hospital, Hai dian District, Beijing, People's Republic of China.
Weihao ChenDepartment of Urology, PLA Navy General Hospital, Hai dian District, Beijing, People's Republic of China.
Xinyu ZhangDepartment of Urology, PLA Navy General Hospital, Hai dian District, Beijing, People's Republic of China.
Yun OuyangDepartment of Urology, PLA Navy General Hospital, Hai dian District, Beijing, People's Republic of China.
Yi WangDepartment of Urology, PLA Navy General Hospital, Hai dian District, Beijing, People's Republic of China.
Changliang XieDepartment of Urology, PLA Navy General Hospital, Hai dian District, Beijing, People's Republic of China.
Maojun ZhouDepartment of Urology, PLA Navy General Hospital, Hai dian District, Beijing, People's Republic of China.
Cuilong LiuDepartment of Urology, PLA Navy General Hospital, Hai dian District, Beijing, People's Republic of China.
PLA Navy General Hospital · CNChinese PLA General Hospital · CNSecond Artillery General Hospital of Chinese People's Liberation Army · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The present study was aimed to examine whether icariin, a traditional Chinese medicine, could improve therapeutic effects of adipose derived mesenchymal stem cells (ADSCs) for diabetes-associated erectile dysfunction (DMED). DMED were induced in rats by intraperitoneal injection of streptozotocin and confirmed by erectile function measurement. Then, rats of diabetic ED were randomly divided to receive the treatment of saline, ADSCs, icariin or ADSCs combined with icariin respectively. Compared with the treatment by ADSCs or icariin alone, intracavernosum injection of ADSCs combined with the following daily gastric gavage of icariin significantly augmented the value of ICP and ICP/MAP (p<0.01). Meanwhile, the survival of transplanted ADSCs was much improved due to the application of icariin. Similarly, immunofluorescent staining analysis demonstrated that the improved erectile tissue structure by combination of ADSCs and icariin was significantly associated with the increased expression of endothelial markers (vWF) (p<0.01) and smooth muscle markers (α-SMA) (p<0.01). Furthermore, the structure changes in corpus cavernosum were further confirmed by the Masson's trichrome staining. To explore the possible mechanism underlying icariin-enhanced therapeutic efficacy of MSCs, we employed an in vitro testing system by introducing H2O2 to imitate oxidative stress condition considering the oxidative environment faced by engrafted ADSCs and anti-oxidative capacity of icariin. In vitro, we found that the addition of icariin considerably reduced the apoptosis of ADSCs, and attenuated the intracellular reactive oxygen species (ROS), the superoxidase dismutase (SOD) activity and the lactate dehydrogenase (LDH). Subsequently, we examined the expression of apoptosis-related proteins and explored the potential signaling pathway through which icariin promoted the survival of ADSCs against oxidative stress. It was demonstrated that icariin significantly inhibited the upregulation of apoptosis-related proteins under oxidative condition, including Bax and cleaved caspase-3, while promoted the expression of anti-apoptotic factor BCL2. These effects were accompanied with the activation of signal molecules, PI3K/Akt and STAT3. The further signal protein inhibition assays exhibited that the suppression of STAT3 abrogated the icariin-mediated anti-apoptotic effects observed above, while did not influence the expression of PI3K/Akt. However, PI3K inhibition could abrogate icariin-mediated STAT3 activation and achieved a similar effect as STAT3 inhibition. Our results suggested that icariin was an effective adjuvant for enhancing ADSC-based therapy of DMEM, which may be ascribed to their protection of ADSCs against oxidative stress via the regulation of PI3K/Akt-STAT3 signal pathway.

Indexed as

Adipose TissueAnimalsApoptosisBlotting, WesternCells, CulturedCell SurvivalCombined Modality TherapyDiabetes Mellitus, ExperimentalDrugs, Chinese HerbalErectile DysfunctionFlavonoidsGraft SurvivalHydrogen PeroxideInjections, IntraperitonealMaleMesenchymal Stem CellsDrugs, Chinese HerbalFlavonoidsHydrogen PeroxideicariinOxidantsPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktSTAT3 Transcription Factor

Identifiers

PMID28350842
PMCPMC5369760
OpenAlexW2599204705

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.